Ionis' 2016 Financial Results Outperform Financial Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Anthropic and Accenture partner on embedded AI safety evaluation
Ionis Pharma (IONS) Tops Q4 EPS by 33c
February 28, 2017 7:09 AM ESTIonis Pharma (NASDAQ: IONS) reported Q4 EPS of $0.21, $0.33 better than the analyst estimate of ($0.12). Revenue for the quarter came in at $160.3 million versus the consensus estimate of $97.47 million.
For earnings history and earnings-related data on Ionis Pharma (IONS) click here.
... More